Full spectrum (or “whole plant”) products contain CBD as well as terpenes and other cannabinoids such as CBG, CBN and trace amounts of THC. Usually these will be in ratios that were naturally-occurring and extracted from the plant and specific strain. Terpenes and cannabinoids are occasionally added back into products as an isolated form to raise the potency of the product.
And, if you do luck out and get a tincture truly containing CBD, you'll likely dish out $200 or so to take 10 to 40 milligrams daily. Since research participants take closer to 1,000 milligrams a day, it's hard to imagine a benefit without drinking the whole (expensive, calorie-dense) bottle, Tishler says. "Most people will adjust their doses based on what they're comfortable spending," Asquith says.
Yes: CBD extracts can’t always be trusted. A 2017 JAMA paper reported that almost 70 percent of all CBD products sold online do not contain the amount of CBD stated on the label. Of the 84 products bought from 31 different companies, 42 percent contained a higher concentration of CBD oil than the label claimed, and 26 percent of the products contained less than the label claimed. The remainder of products contained the labeled amount—give or take 10 percent.
exhaustion and pain that kept her on the couch much of the day. The 58-year-old Seattle speech coach didn’t want to take opioid pain-killers, but Tylenol wasn’t helping enough. Roth was intrigued when women in her online chat group enthused about a cannabis-derived oil called cannabidiol (CBD) that they said relieved pain without making them high. So Roth, who hadn’t smoked weed since college but lived in a state where cannabis was legal, walked into a dispensary and bought a CBD tincture. “Within a few hours of placing the drops in my mouth, the malaise and achiness that had plagued me for weeks lifted and became much more manageable,” she says. She took the drops several times a day and in a few weeks was back to her regular life.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160